ABOUT THIS CONFERENCE
Cardiovascular disease, diabetes, obesity and dyslipidemia,
though traditionally treated as separate entities, are often conditions that
appear together in individuals because of defects in underlying metabolic
processes. Researchers are therefore now seeking compounds that target
biological points of intersection of these related diseases in the hopes of
'killing more birds with one stone.' Or they are approaching drug development
of a compound for a specific disease with a greater awareness of the backdrop
of related conditions.
Join fellow biomedical researchers from academia and
industry at our day and a half conference, Cardio-Metabolic Drug Targets
to discuss the impact of this paradigm change in the way drugs are discovered
and developed in the cardio-metabolic arena and to stay abreast of the latest
targets and drug development candidates in the pipeline.
SUGGESTED EVENT PACKAGE:
September 23: Allosteric Modulators of GPCRs Short Course
September 24 - 25: Novel Strategies for Kinase Inhibitors Conference
September 25: Setting Up Effective Functional Screens Using 3D Cell Cultures Dinner Short Course
September 25 - 26: Cardio-Metabolic Drug Targets Conference
Scientific Advisory Board:
Jerome J. Schentag, Pharm.D., Professor of Pharmaceutical
Sciences, University at Buffalo
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals
Macrophage ABC Transporters: Novel Targets to Promote
Atherosclerotic Plaque Regression by Inducing Reverse Cholesterol Transport
(RCT) Mechanism
Eralp "Al" Bellibas, M.D., Senior Director, Head, Clinical
Pharmacology, The Medicines Company
Targeting PCSK9 for Hypercholesterolemia and Atherosclerosis
Hong Liang, Ph.D., Associate Research Fellow, Rinat Research
Unit, Pfizer
Novel Treatment for Dyslipidemia: Liver-Directed Thyroid
Hormone Receptor-ß Agonist
Rebecca Taub, M.D., Ph.D., CEO, Madrigal Pharmaceuticals
Oral Mimetics of RYGB and GLP-1 in Metabolic Syndromes
Jerome J. Schentag, Pharm.D., Professor of Pharmaceutical
Sciences, University at Buffalo
FGF21-Mimetic Antibodies for Type 2 Diabetes
Jun Sonoda, Ph.D., Group Leader, Scientist, Molecular Biology,
Genentech
Blockade of Delta-Like Ligand 4 (Dll4)-Notch Signaling Reduces
Macrophage Activation and Attenuates Atherosclerotic Vascular Diseases and
Metabolic Disorders
Masanori Aikawa, Ph.D., Assistant Professor, Department of
Medicine, Brigham and Women's Hospital and Harvard Medical
Modulating Glycerolipid Metabolism in Myeloid Cells for
Cardiometabolic Benefit
Suneil K. Koliwad, M.D., Ph.D., Assistant Professor, Diabetes
Center/Department of Medicine, University of California San Francisco
AMPK as a Target in Lipid and Carbohydrate Metabolism
Ajit Srivastava, Ph.D., Adjunct Professor, Pharmacology,
Drexel University; Independent Consultant, Integrated Pharma Solutions, LLC